Immuneering (IMRX) Cash from Operations (2020 - 2024)
Historic Cash from Operations for Immuneering (IMRX) over the last 5 years, with Q4 2024 value amounting to -$14.5 million.
- Immuneering's Cash from Operations fell 2322.94% to -$14.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$55.0 million, marking a year-over-year decrease of 1231.59%. This contributed to the annual value of -$55.0 million for FY2024, which is 1231.59% down from last year.
- As of Q4 2024, Immuneering's Cash from Operations stood at -$14.5 million, which was down 2322.94% from -$13.5 million recorded in Q3 2024.
- Over the past 5 years, Immuneering's Cash from Operations peaked at -$3.5 million during Q3 2020, and registered a low of -$15.5 million during Q1 2024.
- Its 5-year average for Cash from Operations is -$10.4 million, with a median of -$11.1 million in 2023.
- Its Cash from Operations has fluctuated over the past 5 years, first crashed by 15916.69% in 2021, then decreased by 22.63% in 2023.
- Over the past 5 years, Immuneering's Cash from Operations (Quarter) stood at -$5.5 million in 2020, then plummeted by 69.43% to -$9.2 million in 2021, then decreased by 27.16% to -$11.7 million in 2022, then dropped by 0.23% to -$11.8 million in 2023, then decreased by 23.23% to -$14.5 million in 2024.
- Its Cash from Operations stands at -$14.5 million for Q4 2024, versus -$13.5 million for Q3 2024 and -$11.5 million for Q2 2024.